- UroToday Home
- Urologic Oncology
The Latest Research on CRPC with Bone Metastases
Recent Abstracts
-
Bone turnover biomarkers identify unique prognostic risk groups in men with castration resistant prostate cancer and skeletal metastases: Results from SWOG S0421.CRPC w/ bone metastasesJuly 23, 2019
-
Prognostic Value of 18F-Fluorocholine PET Parameters in Metastatic Castrate-Resistant Prostate Cancer Patients Treated with Docetaxel.CRPC w/ bone metastasesMay 9, 2019
-
Incidence of Second Primary Malignancies in Patients with Castration-Resistant Prostate Cancer: An Observational Retrospective Cohort Study in the United States.CRPC w/ bone metastasesMay 1, 2019
-
Radium-223 in asymptomatic patients with castration-resistant prostate cancer and bone metastases treated in an international early access program.CRPC w/ bone metastasesJanuary 11, 2019
-
Patient Selection for Radium-223 Therapy in Patients With Bone Metastatic Castration-Resistant Prostate Cancer: New Recommendations and Future Perspectives.CRPC w/ bone metastasesJanuary 4, 2019
-
Pain predicts overall survival in men with metastatic castration-resistant prostate cancer treated with radium-223.CRPC w/ bone metastasesJanuary 3, 2019
-
Reversibility of castration resistance status after Radium-223 dichloride treatment: Clinical evidence and Review of the literature.CRPC w/ bone metastasesDecember 20, 2018
-
Evaluating radium-223 response in metastatic castration-resistant prostate cancer with imaging.CRPC w/ bone metastasesDecember 3, 2018
-
The Case Against the European Medicines Agency's Change to the Label for Radium-223 for the Treatment of Metastatic Castration-resistant Prostate CancerCRPC w/ bone metastasesNovember 23, 2018
-
Efficacy of Radium-223 in Bone-metastatic Castration-resistant Prostate Cancer with and Without Homologous Repair Gene DefectsCRPC w/ bone metastasesOctober 15, 2018
Beyond the Abstracts
-
Radium-223-Dichloride in Castration Resistant Metastatic Prostate Cancer-Preliminary Results of the Response Evaluation Using F-18-Fluoride PET/CT: Beyond the AbstractCRPC w/ bone metastasesApril 7, 2017
-
Prostate Cancer Cure is Possible: Beyond the AbstractCRPC w/ bone metastasesJanuary 5, 2017
-
The use of radium 223 dichloride in a multidisciplinary approach for treating metastatic castration-resistant prostate cancer, "Beyond the Abstract," by Elisa BorsòCRPC w/ bone metastasesFebruary 11, 2015